# Syntheia Labs Establishes Operations at TSRLabs' Ann Arbor Life Sciences Headquarters

*Growing biotech company will establish operations alongside TSRLabs, creating new opportunities for scientific collaboration in Michigan*




ANN ARBOR, MI, UNITED STATES, September 24, 2026 / EINPresswire.com/ -- TSRLabs, preclinical CRO specializing in testing services and early-stage development strategy, today announced that Syntheia Labs has established operations within TSRLabs' Ann Arbor headquarters. Syntheia Labs provides high-resolution data packages and customized preclinical CRO services designed to predict structural heart risk in active drug pipelines. By combining proprietary, in-house 3D human heart tissue with advanced genomics, the company delivers deep biological clarity that helps partners eliminate preventable, late-stage clinical failures. Led by CEO Merlinda-Loriane Sewavi, MS, Syntheia Labs serves a diverse ecosystem spanning AI computational biology platforms, preclinical CROs, and global pharmaceutical companies.

The addition brings another growing life sciences company into TSRLabs' Ann Arbor facility and creates opportunities for greater interaction between experienced pharmaceutical scientists and emerging biotechnology innovators.

"We have always believed that some of the best scientific ideas develop when experienced people have opportunities to work alongside one another," said Dr. Elke Lipka, President and CEO of TSRLabs. "We are excited to welcome Merlinda and Syntheia Labs to our facility. Supporting growing life sciences companies in Michigan is important to us, and having another innovative team working under the same roof creates opportunities for collaboration that can benefit everyone involved."

For TSRLabs, the agreement builds on the company's long history of supporting early-stage drug developers, academic researchers, and entrepreneurs. In addition to providing integrated preclinical CRO services, TSRLabs has worked extensively with emerging companies and research

teams navigating the scientific and strategic decisions required to advance promising therapeutic programs.

The relationship gives Syntheia Labs a home within an established pharmaceutical research environment as the company continues developing its technology and helping drug development teams make better-informed decisions about which candidates to advance.

“The right environment matters when you’re building technology that reshapes how critical drug safety decisions are made. At Syntheia Labs, our goal is to give development teams absolute clarity on structural cardiac risk. Our mission leverages our proprietary 3D human heart tissue and high-resolution genomics long before pipelines face costly clinical trial failures,” said Sewavi. “Co-locating with TSRLabs surrounds our data and lab teams with deep preclinical expertise. It’s an ideal setup as we scale our CRO services, partner with AI and pharma leaders, and reinforce Michigan’s position as a powerhouse for biotech innovation.”

Syntheia Labs has received investment from Red Cedar Ventures, 84|90 and is a graduate of the Henry Ford Innovations x MSU Research Foundation accelerator. Its move into TSRLabs’ headquarters marks another stage in the company’s growth and adds to the concentration of emerging life sciences innovation in the Ann Arbor region.

“The midwest region has tremendous scientific talent and a long history of pharmaceutical innovation,” added Dr. Lipka. “We want to see more promising companies build here, grow here, and have access to the scientific experience they need to succeed. Welcoming Syntheia Labs is another step in that direction.”

Learn more about partnering opportunities with TSRLabs at https://www.tsr-labs.com/partnering.

About TSRLabs

TSRLabs. is a woman-owned preclinical contract research organization (CRO) specializing in formulation development, bioanalysis, exploratory toxicology, and pharmacokinetic strategies to guide human dosing schedules. Based in Michigan, TSRLabs supports pharmaceutical, biotechnology, academic, and government partners with a science-first approach that goes beyond standard testing. As a preclinical CRO, TSRLabs delivers a focused set of services that help research teams move drug candidates forward. Each solution is designed to reduce development risk, generate high-quality data, and support better decision-making earlier in the process. Learn more at www.tsr-labs.com.

About Syntheia Labs

Syntheia Labs is a tissue engineering biotechnology company that builds high-resolution data packages and offers tailored preclinical CRO services to detect structural cardiac risk in drug

candidates before clinical trials. Powered by proprietary 3D human heart tissue produced entirely in-house and integrated with high-resolution genomics, Syntheia Labs delivers actionable biological datasets to both AI computational modeling partners and pharmaceutical companies. Backed by Red Cedar Ventures, 84|90 and a graduate of the Henry Ford Innovations x MSU Research Foundation accelerator, the company is headquartered in Ann Arbor, Michigan. Learn more at https://www.syntheiabio.com/ or visit https://www.linkedin.com/company/syntheia-labs on LinkedIn.

Don F. McLean
McLean Media
+1 734-716-4182
email us here

---

This press release can be viewed online at: https://www.einpresswire.com/article/944338448

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.